ifferentiation arrest is a common feature of many cancer cells. Although intratumoral clonal heterogeneity is well documented, a detailed understanding of how the complement of driver mutations within a clone contributes to differentiation arrest is lacking. Furthermore, although genetic and functional intratumoral heterogeneity clearly helps determine clinical outcomes in cancer therapy 1, 2 , few studies have investigated the relationship between clonal structure and therapy response, particularly for therapies targeting oncogenic epigenetic processes. With an average of 13 somatic mutations per patient, arranged in an limited number of clones 3 , AML has a simpler genomic context than most cancers, thus providing a potential paradigm to answer these questions.
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Somatic mutations in the conserved arginine residues R140 and R172 in isocitrate dehydrogenase 2 (IDH2) occur in 15-25% of patients with AML [4] [5] [6] . The mutant proteins have neomorphic activity producing (R)-2-hydroxyglutarate (2-HG), which competitively inhibits α -ketoglutarate-dependent enzymes including the TET family of 5-methylcytosine hydroxylases and Jumonji-C domain histone demethylases 7, 8 . This inhibition leads to DNA hypermethylation 9 , increased repressive histone methylation 8 and impaired hematopoietic differentiation, effects reversed by mutation-based IDH inhibition in model systems 8, [10] [11] [12] .
We have recently shown that enasidenib (AG-221/CC-90007), a first-in-class, allosteric inhibitor of mutant IDH2 (ref. 13 ), decreases serum 2-HG, reverses DNA hypermethylation and promotes hematopoietic differentiation in preclinical models 13, 14 . In a phase 1/2 clinical trial, enasidenib monotherapy produced a response rate of 40.3% in relapsed/refractory patients with AML 15 . In most of those responding patients, terminally mature blood cells were IDH2 mutant, in agreement with a response due to enasidenib-induced differentiation of IDH2-mutant cells 16 . However, in 9/71 (12.6%) responding patients, IDH2-mutant cells were eliminated from peripheral blood cells 16 . A failure to respond to enasidenib was associated with a higher comutational burden and NRAS mutations 16 . Finally, most patients who initially responded eventually relapsed. These initial studies did not assess which clones differentiated in response to enasidenib or the clonal mechanism of acquired enasidenib resistance. Here, we addressed these two questions by studying sequential samples from a subset of trial patients. We found marked variation in the degree of differentiation arrest of mutant IDH2 clones. The restoration of differentiation by inhibition of mutant IDH2 was also clone dependent, varying among patients and arising from either ancestral or terminal clones. In a minority of patients, differentiation occurred from wild-type progenitor cells, in agreement with molecular remission in a subset of patients. Acquired resistance to enasidenib, leading to differentiation arrest and relapse, did not occur as a result of second-site mutations in IDH2. Instead, differentiation arrest was restored by multiple mechanisms through clonal evolution or clonal selection.
Results
Patient cohort studied. The trial enrolled 176 relapsed/refractory IDH2-mutant patients with AML 15 . Here, we studied a cytogenetically and genetically representative subset of 37 patients that was enriched in enasidenib responders (30/37 responders; Supplementary Fig. 1a-c ). An extended mutational profile was determined in 33/37 patients through either whole-exome sequencing (WES) (16/36 patients at read depth of 19-843× , average 121× at loci where variants were called) or targeted resequencing (17/36 patients) (Supplementary Tables 1 and 2 ). Compared with the entire trial cohort, the patient cohort studied here had similar serum baseline 2-HG levels, and the mean level of 2-HG suppression was similar in the two cohorts (i.e., on-target response to enasidenib; Supplementary Fig. 1d ,e).
Enasidenib rebalanced progenitor and precursor compartment sizes and restored progenitor function. In AML, there are two orthogonal potential hierarchies ( Supplementary Fig. 2a ). First, there is clonal hierarchy with an initiating clone, and transitional and terminal clones. We refer to all nonterminal clones as ancestral clones. These mutant clones exist in a second hierarchy, a hematopoietic cell hierarchy. AML-initiating mutations occur in stem cells or long-lived progenitor cells, but initiating clones are not usually arrested in differentiation [17] [18] [19] . However, with acquisition of additional transforming mutations and epigenetic alterations, clones do not complete maturation. In the fully transformed state, hemopoiesis in human AML is dominated by expansion of either progenitor-like cells, presumably because of a differentiation block between progenitor and downstream precursor cells 20 , or, less commonly, precursor-like cells, presumably because of a differentiation block between precursor and mature cells 21 . In both cases, expanded leukemic progenitor-like or precursor-like populations have functional leukemic stem cell activity 20, 21 . Thus, we set out to address three questions: (i) where are individual clones arrested in the hematopoietic hierarchy; (ii) which clones respond to mutant IDH2 inhibition by differentiating; and (iii) which clones are responsible for loss of response to enasidenib after an initial response, and through what mechanism?
The experimental approach is shown in Supplementary Fig. 2b . We first performed flow-cytometric quantification of hematopoietic stem/progenitor (Lin -CD34 + CD117 
CD34
+ cells were also quantified. 11/15 patients had abnormally expanded progenitor-like compartments (mainly lymphoid-primed multipotent progenitor (LMPP)-like and granulocyte-macrophage progenitor (GMP)-like populations; termed progenitor AML) and 4/15 abnormally large myeloid precursor-like populations (termed precursor AML). The ratio of progenitor to precursor AML was consistent with findings in previous studies 20, 21 . Next, we analyzed the bone marrow (BM) stem/progenitor/ precursor populations in five patients who achieved complete remission (CR) with enasidenib (Fig. 1b,c) . In all five patients, there was near normalization of the sizes of the stem/progenitor compartments. Before treatment, two patients had pathologically expanded LMPP-and GMP-like progenitor populations (patients #201-023 and #201-011), and two patients had expanded myeloid precursor compartments (#201-010 and #203-002). Functionally, Lin -CD34 + progenitor cells from these five patients in CR formed myeloid-erythroid colonies nearly as efficiently as normal cells, in contrast to cells from patients who did not achieve CR ( Fig. 1d and Supplementary Fig. 3c,d) . Thus, enasidenib therapy rebalanced the sizes of hematopoietic stem/progenitor/precursor/ mature populations at CR with reacquisition of normal myeloid progenitor function.
Wild-type hemopoiesis occurs occasionally with enasidenib therapy. Next, we investigated the clonal basis of differentiation. In principle, enasidenib could have directly or indirectly restored differentiation from wild-type cells, ancestral clones or terminal clones in a clonal hierarchy (Fig. 2a) . We established the clonal basis of response in six patients by using samples taken at multiple time points before and through treatment, including relapse (Fig. 2b) . We used WES and karyotyping of BM mononuclear cells (BMMNCs) to determine chromosomal copy number and mutational changes (Supplementary Tables 2 and 3 ). Next, we used WES data to design patient-specific mutation panels to test variant allele frequencies (VAFs) of mutations in unsorted BMMNCs and flow-cytometry-sorted hematopoietic stem/progenitor/precursor/mature cell populations and genotype flow-cytometry-sorted single cells and hematopoietic colonies derived from single cells (Supplementary Table 3) . A combination of all these data was used to establish clonal structures. Details on setting false-positive and false-negative thresholds in single-cell genotyping (SCG) are presented in Methods.
In our initial study, 9/29 patients who achieved CR, for whom samples were available, had loss of mutant IDH2 peripheral blood cells (complete molecular remission in peripheral blood 16 . However, it was unclear whether these differentiated blood cells were truly wild type or were from genetically mutant clones that lacked mutant IDH2. We studied this question in a patient who had mutations in IDH2 (I), PEX26 (P), FEZ2 (S208T substitution; F), DNMT3B (D), ZCCHC1 (official symbol LIN28A; Z), NPM1 (N) and ELMO3 (E) in AML blasts before enasidenib treatment (#201-022, Fig. 2c) , and who achieved mutant IDH2 molecular remission. Before therapy, imputation from VAF suggested the presence of wild-type cells and three possible mutant clones: a clone with IDH2 mutation alone (I), a clone with genotype IPFDZN and a minor clone that was either IPFDZNE or IE ( Supplementary Fig. 4a-c) , although the exact clonal structure could not established unambiguously ( Supplementary Fig. 4d-h ). At CR, the VAF of all mutations was < 1.6% ( Fig. 2c and Supplementary Table 4 for depth of sequencing). Concordantly, at CR, most (94.6%) of the 111 individually genotyped hematopoietic colonies did not contain any mutations present pretherapy (Fig. 2d) . Functionally, the colonies produced a normal ratio of myeloid to erythroid colonies, in agreement with a wildtype genotype (Fig. 2e) . Thus, in a minority of patients, enasidenib therapy resulted in restoration of wild-type terminal blood cell production and progenitor function from wild-type cells.
Enasidenib restored differentiation from ancestral and terminal clones in a clone-dependent manner. In one patient, enasidenib promoted differentiation from an ancestral clone (#201-023, Fig. 3 ). WES and targeted resequencing of BMMNCs before enasidenib treatment detected mutations in SRSF2 (S), IDH2 (I), ASXL1 (A) and GATA2 (G), and two mutations in RUNX1 (R and r) ( HSC   MPP   LMPP   GMP   CMP   MEP   #201-010  #201-020  #203-002   Precursor  expanded   #104-003  #201-011  #201-023  #104-036  #111-035  #104-038  #201-009  #900-003  #104-021  #104-009  #201-007  #201-017   0%   10%   20%   30%   40%   50%   60%   70%   80%   90%   100%   Normal  BM   100%   0%   10%   20%   30%   40%   50%   60%   70%   80%   90%   0%   10%   20%   30%   40% 50% + cells from normal BM (n = 4 biologically independent samples), enasidenib-treated patients in CR (n = 5 biologically independent samples) and enasidenib-treated patients not in CR (n = 3 biologically independent samples). Patient samples were plated with addition of enasidenib (1 µ M) to semisolid medium. Error bars, s.e.m. P values were determined by two-sided Student's paired t test. Tables 2 and 3 ). Pretherapy imputation of clonal structure on the basis of VAF in unsorted BMMNCs by exome sequencing and targeted resequencing suggested initial acquisition of an SRSF2 mutation (clone S) followed by an IDH2 mutation (clone SI) followed by acquisition of ASXL1 mutation, the two RUNX1 mutations and GATA2 mutation ( Supplementary Fig. 5a and Supplementary  Tables 2 and 3 ). At CR, only mutations SRSF, IDH2 and ASXL1 were detected in mature cells, thus supporting the existence of an SIA clone that preferentially completes terminal maturation in the presence of enasidenib ( Supplementary Fig. 5a-c) .
To clarify clonal structure, and to position clones within the hemopoietic hierarchy, we performed targeted resequencing for driver variants in 63 single cells and cell populations, from flowcytometry-sorted progenitor and mature myeloid cell compartments, from both pretherapy and CR samples (Fig. 3a,b and Supplementary Table 3 ). The results confirmed a linear clonalevolution pattern: clone SI preceded clone SIA and was followed by clones that sequentially acquired RUNX1 mutations (clones SIAR and SIARr), and finally the terminal clone, which acquired a GATA2 mutation (SIARrG). The mutational profiles in four single cells did not fit into this clonal-evolution pathway. We detected a single cell with an ASXL1 mutation (clone A) and three single cells with both ASXL1 and SRSF2 mutations (clone AS). In three cells with genotype AS, we detected allele dropout (ADO) of the IDH2 allele in two of three cells. Consequently, we were unable to determine the mutational state of IDH2 in those two cells. In contrast, out of 12 cells of the SI clone, ADO of the ASXL1 allele was detected in only three cells ( Supplementary Fig. 12a ). Thus, although our results do not exclude a rarer parallel clonal-evolution pathway in which clones A and AS exist and do not acquire mutations in the order shown in the main pathway, they also are consistent with these cells being part of the main clonal-evolution pathway.
Pretherapy, 90% of BMMNCs were progenitors (LMPP and GMP) (Figs. 1c and 3d) , and 90-100% of these leukemic progenitors were SIARrG (Fig. 3c) . Thus, the SIARrG clone is arrested in differentiation at the progenitor stage and expands to dominate the BM. Less than 10% of BMMNCs were mature myeloid cells (Figs. 1c and 3d ). We were able to genotype only eight mature myeloid cells pretherapy (Fig. 3c) , and they were composed of a mixture of wild-type cells and cells with genotypes A, SI, AS and SIA. At CR, the mature myeloid cell compartment comprised 60% of BMMNCs (Figs. 1c and 3d) , and 85% of mature cells had the SIA genotype (Fig. 3d, Supplementary Fig. 5b and Supplementary Table 3 ).
The progenitor compartment made up only 20% of BMMNCs at CR (Figs. 1c and 3d ) and was composed of mixed ancestral clones SI, SIA and SIAR, but not the terminal clone SIARrG. Concordantly, most colonies generated by progenitors at CR were SIA, and a minority had the SI or SIA genotype (Fig. 3e) . The ratio of myeloid to erythroid colonies was within normal limits ( Fig. 3f ) Together, these data demonstrated a complex clone-dependent pattern of enasidenib-induced differentiation with production of mature myeloid cells sustained principally by a self-renewing ancestral SIA clone.
In four patients, differentiation of mature cells was principally seen from terminal clones (Fig. 2b) . In patient #201-011, WES (Supplementary Table 2 ) and targeted resequencing of BMMNCs revealed two mutations in DNMT3A and mutations in IDH2, ASXL1 and XPO1 pretherapy that persisted at different VAFs at CR (Supplementary Table 3 and Supplementary Fig. 6a ). However, it was not possible to impute the clonal structure from the VAF ( Supplementary Fig. 6b ). We genotyped 110 single cells, pretherapy and at CR (Fig. 4a) . The results revealed an initiating DNMT3A clone (clone D) that acquired an IDH2 mutation (clone DI) (Fig. 4b) . Subsequently, there was a branching clonal structure with two terminal clones; one acquired an XPO1 mutation (clone DIX), whereas the other acquired two mutations (a second DNMT3A mutation and an ASXL1 mutation; clone DIdA). SCG suggested GM/E ratio (95% confidence interval) that the DIdA clone might have arisen through convergent evolution through intermediate DId and DIA clones. There is a caveat with this interpretation, because ADO was detected in six of seven DIA-clone cells ( Supplementary Fig. 12c ). In the DId cells, although there were no heterozygous germline single-nucleotide polymorphisms (SNPs) in the sequenced ASXL1 gene, the estimated ADO frequency of the ASXL1 allele was 12.1%. Thus, the DIdA clone might also have arisen through just one mutational pathway.
Before enasidenib treatment, 89% of BMMNCs were leukemic progenitors (LMPP and GMP) virtually exclusively composed of the DIX clone (Fig. 4c,d) . A small mature myeloid population was present before enasidenib and was composed of the DIdA clone ( Supplementary Fig. 6c ). These observations suggest that the IDH2 mutation in the context of the DIdA clone is not fully effective at imposing a complete differentiation block, whereas the same IDH2 mutation in the context of the DIX clone fully arrests at a progenitor stage.
At CR, 82% of BMMNCs were composed of mature myeloid cells, 85% of which were a mix of two terminal branching clonesDIdA (54%) and DIX (31%)-thus suggesting that enasidenib promoted differentiation from both terminal clones (Fig. 4c,d and Supplementary Table 3 ). To address which progenitors contribute to mature cell output, we genotyped single flow-cytometry-sorted progenitors. The DIdA clone dominated mature GMP, CMP and MEP progenitor compartments (Fig. 4c,d ). In contrast, clone DIX was detected only in the more immature LMPP progenitor compartment. GMP, CMP and MEP are more clonogenic than LMPP 20, 22 , and concordantly, ~95% of colonies had the DIdA genotype ( Fig. 4e ) and were myeloid biased (Fig. 4f) . Interestingly, there was a substantial decrease in the size of the LMPP compartment at CR compared with pretherapy ( Fig. 4d) (1,240-fold decrease within the Lin -compartment and 81-fold decrease within the CD34 + compartment). In three additional patients, the terminal clone contributed to mature myeloid cells at CR, on the basis of imputed clonal structures, genetic analysis of mature myeloid cells at CR (patient #201-010, Supplementary Fig. 6d ,e) and genotyping of myeloid colonies at CR (patient #201-027, Supplementary Fig. 7a-d ; patient #201-006, Supplementary Fig. 7e-h ). The depth of coverage for each of the mutations in all three patients is shown in Supplementary Table 4 .
In summary, enasidenib therapy provides relief of differentiation arrest at a progenitor-like or precursor-like stage, normalizing the sizes of these abnormally expanded compartments. The ability of mutant IDH2 to impose differentiation block is dependent on the context of coassociated mutations within a clone. Consequently, the efficacy of enasidenib-induced differentiation is also likely to depend on the mutational landscape within a clone.
Relapse of IDH2-mutant patients on enasidenib occurs through clonal selection/evolution and not second-site mutations in IDH2.
Although responding patients have a median survival of 18-21 months, many patients relapse 15 . To study the mechanisms leading to relapse, we measured 2-HG levels in 16 patients at diagnosis and relapse, mutational profiles in 12 patients (by WES in 11 cases and by targeted sequencing in one case) and performed karyotype analysis in 11 subjects (Fig. 5a,b and Supplementary Table 5 ). We did not detect second-site IDH2 mutations at relapse in any patient but instead documented seven patterns of clonal evolution/selection with acquisition of recurrent AML-associated genetic changes (Fig. 5a ). These were recurrent missense mutations in myeloid malignancy, or nonsense and frameshift mutations in cancers, as documented in the COSMIC database (http://cancer.sanger.ac.uk/cosmic/). For patient #201-007, mutations were detected before relapse, but increased in frequency at relapse (Supplementary Table 3 ).
In 14/16 patients, 2-HG levels remained suppressed between best response (CR or PR) and relapse, thus suggesting that the drug was on target in suppressing neomorphic enzyme function (Fig. 5b) . However, in two patients (#201-014 and #201-022) rising 2-HG 1%. Additional data in Supplementary Fig. 12c . c, Clonal composition in different immunophenotypic compartments in pre-ENA and CR samples, as in Fig. 3c . d, Clonal contribution (vertical bars) to immunophenotypic BM hematopoietic populations in pre-ENA and CR patient samples (horizontal bars). Data are from SCG, except for the mature granulocyte-macrophage population in the pre-ENA samples, in which the flow-cytometry-sorted cell population was genotyped (asterisk). e, Clonal contribution to colonies grown from CR samples (percentage of genotyped, individually picked colonies), as in Fig. 3e . f, Lineage affiliation of colonies from BM CD34 + cells purified from the CR sample, as compared with normal CB (as in Fig. 2e ). levels and BM leukemic cells (blasts) were seen (Fig. 5c,d ). Exome sequencing revealed IDH1 mutations encoding R132C or R132H, albeit accompanied by other genetic abnormalities, some of which are recurrent in AML (point mutations in RUNX1 and NPM1 and t(3;12)) (Fig. 5e,f) . These IDH1 mutations were previously undetectable by high-depth next-generation sequencing (NGS; 10,000× ) before enasidenib therapy. Unexpectedly, in both cases, the VAF indicated that IDH1 mutations were present in IDH2-mutant clones.
Relapse was also associated with increasing VAF of oncogenic gain-of-function mutations in two genes encoding cytokine receptors: CSF3R (#104-021, Supplementary Fig. 8a,b) and FLT3 (#201-013 and #201-004, Supplementary Fig. 8c,d ; #201-007, Supplementary  Fig. 9f-h ) and predicted loss-of-function mutation in CBL, encoding a negative regulator of cytokine signaling (#201-004, Supplementary  Fig. 8d ). For patient #104-021, we could not resolve the clonal structure from targeted resequencing of BMMNCs ( Supplementary  Fig. 8b and Supplementary Table 2 ), but genotyping of 214 single cells before enasidenib and at relapse (Fig. 6a ) demonstrated an initiating DNMT3A/IDH2-mutant clone that spawned the major clone with a recurrent U2AF1 mutation (DIU clone). A minor DIUF clone encoding a FLT3 D200E variant (not previously described in AML) was also present before enasidenib treatment. At relapse, the major clone in the expanded arrested LMPP and GMP compartments had acquired an oncogenic T618I mutation in CSF3R, which has been well described in myeloid leukemias 23 (DIUC clone). DIUC further evolved, acquiring a variant in NFKB1 that has not been described previously in AML. Mutations in both CSF3R and NFKB1 were detectable at the threshold of sensitivity before enasidenib (Supplementary Fig. 8a ).
Relapse and reimposition of differentiation block were also associated with previously described mutations in hematopoietic transcription factors in myeloid cancers. These included frameshift mutations in RUNX1 (Fig. 5e and Supplementary Fig. 8e , one of which has previously been described in AML (RUNX1 F416fs) 24 ) and BCORL1 (ref.
25
); nonsynonymous variants in the DNA-and protein-partner-binding N-terminal zinc finger of GATA2 ( Supplementary Fig. 8d ) 26, 27 and in one of the zinc fingers of BCL11A 28 ( Supplementary Fig. 8c ). In all patients, these mutations were not detected before enasidenib treatment.
Deletion of all (monosomy 7) or part (del 7q) of chromosome 7 is common in myeloid malignancy 29 . Chromosomal abnormalities were present in 18% of the enasidenib cohort 15 and in 20% of the cohort studied here (Supplementary Fig. 1 ). Del 7q was detected in 4/12 patients who relapsed (#201-010, #201-007, #201-019 and #201-003) (Fig. 5a and Supplementary Table 5) but is not enriched in relapsed patients (M.A. and A.T., unpublished data). In all four patients, this deletion was detected either cytogenetically or by WES before enasidenib therapy (Supplementary Tables 2 and 5 ). In three of the four cases, the del 7q clone was selected at relapse ( Supplementary Fig. 9a-e,k,l) . In one case in which that clone was not selected, it was the dominant clone before therapy and at relapse ( Supplementary Fig. 9g-j) .
Clonal evolution at relapse also highlighted variants in genes less well studied in AML, including NFKB1 (encoding M216I; Fig. 6a-d) , DDX1 (encoding G699A; Supplementary Fig. 8c ), MTUS1 (encoding Q781H; Supplementary Fig. 9f-i) , DHX15 (encoding R222G) and DEAF1 (encoding N372K; Fig. 6e-h ). Of these, the acquisition of the latter two variants by patient #201-011 at relapse was notable. Before enasidenib, the patient had expanded LMPP and GMP populations composed of an arrested DIX clone (Fig. 4b) . At CR, the DIX clone was able to differentiate but persisted within only the LMPP com- partment (Fig. 4d) . At relapse, we detected 30 cells with DIX mutations that acquired a missense mutation in the DExD/H-box helicase gene DHX15 (encoding R222G; mutation H), seven cells with the DIX mutations that had acquired a variant in the transcription factor gene DEAF1 (encoding N372L; variant F) and 12 cells with the DIXHF variants (Fig. 6e,f) . However in six out of seven DIXF cells, there was ADO for the DHX15 allele encoding the R222G mutation, and therefore we are unable to determine whether the R222G mutation was present in those cells (Supplementary Fig. 12c) .
Acquisition of the additional DHX15 and DEAF1 mutations was associated with differentiation arrest and a reexpansion of LMPP and GMP progenitor compartments, comprising 89% of MNCs. 83% of LMPP cells were composed of the DIXH and DIXHF clones, whereas in the GMP-like compartment there was a more even contribution by the DIXHF, DIXH and DIXF clones (Fig. 6g,h ). Finally, both DHX15 and DDX1 regulate RNA splicing. Human DHX15 is structurally closely related to its yeast homolog, Prp43 (refs 30, 31 ). Both proteins have been shown to contribute to disassembly of splicesomes, efficient debranching and turnover of excised introns 32, 33 . DHX15 R222G mutations have been previously described in AML 34, 35 . To determine whether acquisition of DHX15 R222G results in altered splicing, we performed RNA-seq of AML blasts at relapse from patient #201-011 and compared splicing with that in AML cells from the same patient that were wild type for DHX15 at trial entry (Supplementary Fig. 8f ). In cells expressing DHX15 R222G, compared with cells wild type for DHX15, there were alterations in exon skipping and intron retention. DDX1 is a DEAD-box RNA helicase with 5′ single-stranded RNA exonuclease activity that has been postulated to have multiple roles in RNA metabolism 36 . DDX1 G699A has not been previously described as a cancer-associated mutation nor has its effect on RNA splicing been studied. Our data show an increase in intron retention and use of alternative 5′ and 3′ splice sites, and a decrease in spliced exons in mutant compared with wild-type AML cells from the same patient ( Supplementary Fig. 8g ).
Discussion
This study of the clonal response and acquired resistance in sequential paired samples from patients with AML treated with an IDH2 inhibitor extends prior preclinical studies 13, 14 . Before enasidenib treatment, there were complex patient-and clone-specific patterns of differentiation arrest. At CR, wild-type-dominated cellular reconstitution was less common but did occur. More commonly, enasidenib caused a clone-specific differentiation response, either from ancestral or terminal clones, thus leading to near normalization of the sizes and functionality of progenitor and precursor hematopoietic compartments with an altered clonal mix. Acquired resistance was never due to a second-site mutation in the same IDH2 allele but instead was due to either clonal evolution or clonal selection. At least seven different mutational mechanisms led to reimposition of differentiation arrest (Supplementary Fig. 10 ).
In most patients, enasidenib was unable to promote terminal differentiation and eradication of IDH2-mutant clones; ancestral and/or terminal clones remained at CR. In patients with restitution of wild-type hemopoiesis, we infer that enasidenib probably promoted terminal differentiation of arrested self-renewing IDH2-mutant cells, thereby allowing normal cells to dominate hemopoiesis. Longer-term clinical follow-up of patients with molecular CR should indicate whether patients with molecular CR have better clinical outcomes and, if they relapse, the clonal origin of relapse. More generally, understanding the molecular mechanisms of relief from differentiation arrest by IDH2 inhibitors will require in-depth study of the changing patterns of epigenetic marks and transcriptional programs within highly purified and clone-specific hematopoietic stem, progenitor and precursor populations, before and after drug exposure, because transcriptional and epigenetic profiles are highly plastic through differentiation.
Drug resistance to targeted cancer therapy arises through multiple mechanisms. Resistance to kinase inhibitors in AML 37, 38 , chronic myeloid leukemia 39 , chronic lymphoid leukemia 40 and lung cancer 41, 42 often involves second-site mutations in the mutant allele modulating drug or substrate binding or copy-number changes in the mutant kinase. We did not observe such changes in enasidenibtreated patients.
Acquired resistance to IDH2 could arise through either epigenetic or genetic mechanisms or a combination thereof. In most patients, 2HG remained suppressed at relapse, thus suggesting that enasidenib remained on target, and relapsed clones were not dependent on mutant IDH2. In hematologic malignancies, genome-wide epigenetic variation (DNA methylation, for example) can be several orders more variable than genetic change [43] [44] [45] ; moreover, this variation is somatically heritable and is subject to selection. Locus-specific DNA methylation (epiallele) variation shows dynamic changes in AML between diagnosis and relapse, and it can occur with distinct kinetics, such that some patients may have a high epiallele diversity and low somatic-mutation burden or vice versa 45 . In melanoma, resistance to a B-RAF inhibitor arises in rare cells through stochastic, transient variation in gene expression that is selected for by therapy 46 . This mechanism is consistent with prior findings on chromatinmediated drug resistance in cancer cell lines 47 . Clones acquiring gene mutations, or gross genetic changes, have previously been reported in therapy-resistant chronic lymphocytic leukemia 48 and medulloblastoma 49 . Acquisition of an IDH1 mutation in two patients is an example of how this resistance may occur. Here, AML propagation is likely to be highly dependent on high 2HG. 2HG addiction may be AML-cell autonomous, or alternatively the 2HG requirement may be in BM-niche supporting cells or other non-AML cell populations. AML clonespecific and non-AML cell-specific analysis of the effects of 2HG on epigenetic and transcriptional programs and metabolism of cells 50 is needed to understand this dependency. Other examples of genetic changes leading to enasidenib resistance include gainof-function mutations in proliferative cytokine signaling pathways and loss of, or altered, function in transcriptional regulators of hemopoiesis. However, mutations in the RAS pathway that are correlated with a failure of initial response 16 were not associated with acquired resistance.
We also detected variants at relapse that were not previously well studied in AML. An example of this is the DHX15 R222G mutation, which has recently been described in RUNX1-RUNXT1 AML 34 . The yeast homolog of DHX15, Prp43, regulates RNA splicing and ribosome biogenesis. Loss of wild-type DHX15 and overexpression of mutant DHX15 increases alternative splicing. In contrast, a role of DEAF1 has not been previously described in normal or malignant hemopoiesis. Interestingly, DEAF1 is a paralog of the transcription factor RUNXT1. DEAF1 is expressed throughout hemopoiesis but particularly in GMP and AML blasts 21 . In nonhemopoetic tissues, it binds LMO4, a member of the LMO transcriptional adaptor-protein family. In blood cells, LMO2, a closely related LMO family member, partners with transcription factors including GATA, E-box proteins and LDB1, thereby forming regulatory and oncogenic protein complexes. Thus, the role of DEAF1 in hemopoiesis and its interaction with DHX15 merits further study. More broadly, a deeper mechanistic understanding of how wild-type IDH2 promotes hematopoietic differentiation, which is currently poorly understood, should also increase understanding of how bypass pathways could reimpose differentiation block, for example by altering transcriptional programs, as seen in resistance to BET-inhibitor therapy 51 . Finally, this study demonstrates how any cancer therapy alters clonal structure across a fully transformed and premalignant cellular hierarchy. By defining clonal structures and mapping where clones were arrested across differentiation in purified hematopoietic compartments, we obtained a previously unavailable view of where different clones were arrested. These findings provide the necessary information to study why clones are arrested at different stages of differentiation. Furthermore, analysis of sequential samples through therapy shows how clones differentially respond to therapy. This information provides a basis to study clone-specific relief of IDH2 inhibition. More generally, our approach could be applied to any cancer therapy in which single-cell suspensions and purification of cells at different stages of differentiation are possible. This approach would then provide a clone-specific understanding of how therapy alters clonal structure through a cellular hierarchy.
Our approach also provides insights toward a rational basis for combination therapies to decrease drug resistance.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0115-6.
Measurement and analysis of 2-hydroxyglutarate. Serum samples were collected within 28 d before the first dose of enasidenib ('screening') and/or predose on day 1 of each treatment cycle. 2-HG concentrations were determined by liquid chromatography and tandem mass spectrometry (Covance, according to the manufacturer's validated method). Baseline 2-HG was taken as the average value of the screening sample and predose cycle 1 sample, or the value of either sample if both were not available. Percentage suppression of 2-HG was determined by comparing the lowest level of 2-HG observed after treatment relative to baseline.
Hematopoietic cell immunophenotyping.
Frozen BMMNCs from normal donors or AML samples were washed with Iscove's modified Dulbecco's medium (Thermo Fisher), 10% FBS (Sigma) and 1 mg/ml bovine pancreatic DNase I (Sigma). Cells were stained for flow cytometry with the antibodies listed in Supplementary  Table 8 . Analysis was carried out on either BD LSR Fortessa or BD FACSAria Fusion (Becton Dickinson) instruments. Antibodies used for the lineage (Lin) depletion were: anti-CD2, anti-CD3, anti-CD4, anti-CD8a, anti-CD10, anti-CD19, anti-CD20 and anti-CD235a (Supplementary Table 8 Table 2 was analyzed with highly multiplexed PCRbased targeted resequencing with a custom panel of 373 amplicons covering areas of high-frequency AML mutations in 35 genes, by using the Fluidigm Access Array platform, as previously described 6 .
Mutational analysis by whole-exome sequencing. Genomic DNA from flowcytometry-sorted AML blasts or CD3-positive cells (germline control) was purified with Allprep DNA/RNA Mini or Micro Kits (Qiagen). After exome capture with a SureSelect V5 Mb All Exon kit (Agilent), paired-end 100-bp sequencing was performed on the HiSeq2000 (Illumina) platform. Read alignment to the hg19 reference genome was performed with the BWA algorithm (v0.7.10), with corrections with GATK (v3.3.0) after removal of PCR duplicates. Variant detection was carried out with VARSCAN (v2.3.7). Somatic variants (Supplementary Table 2) were selected with the following criteria: minimum depth 8× , VAF > 10% in AML blasts and < 10% in germline control, and P < 0.001. All variants were manually inspected with IGV (v2.3) software. Artifactual variants from DNA oxidation in which read-pair orientation bias was observed (i.e., predominant F2R1 orientation for C-to-A variations or F1R2 for G-to-T variations) were filtered out. The median depth at the positions reported in the Supplementary Table 2 was 121 (range 19-843).
Selection of mutations for targeted resequencing in populations and single cells. On average, 23 somatic mutations were detected per AML sample by WES. We selected mutations for further validation by targeted resequencing and SCG on the basis of the following criteria: (i) known recurrent mutations in AML and (ii) nonrecurrent mutations in genes commonly mutated in AML. In addition, mutations not meeting above criteria, but in which the VAF varied by at least 5% between sequential samples in the same patient, were of interest because these might be markers of clonal shifts. When multiple mutations had similar VAFs and showed similar patterns of change in VAFs in sequential samples, a representative mutation was selected. This procedure is illustrated in the example from patient #201-011 ( Supplementary Fig. 11a ). Mutations that were not validated by targeted resequencing were excluded in subsequent data analysis. Chromosomal loss of heterozygosity detected by WES (or by karyotyping) was examined on the basis of germline SNPs present in the affected chromosomal region.
Mutational analysis by targeted resequencing. Mutations detected by targeted resequencing in hematopoietic cell populations are shown in Supplementary  Table 3 . The average and range of read depth for each mutation are shown in Supplementary Single-cell genotyping. Mutations interrogated by SCG are listed in Supplementary Table 3 . Single cells were flow-cytometry-sorted into 96-well plates containing 2 µ l of phosphate-buffered saline. WGA was carried out with a Single Cell RepliG Kit (Qiagen). Briefly, after cell lysis, alkali denaturation and neutralization, a master mix containing Phi29 polymerase, dNTPs and random oligonucleotide primers was added. WGA was carried out at 30 °C for 8 h and was followed by heat inactivation. Diluted (1:20) amplified DNA was used in single or multiplex PCR with primers relevant to the sample and High-Fidelity Phusion Taq polymerase (NEB) or KAPA2G Multiplex DNA Polymerase (KAPA Biosystems). Barcoding and sequencing oligonucleotides were added by PCR, and sequencing was performed on the Illumina MiSeq platform. ~94% of reads had Phred scores > 30. A threshold of 50 reads was set for analysis inclusion. VAF thresholds for determining detection of mutations were determined by genotyping 48 single cells derived from normal BM, and were set at the 95% confidence level (mean ± 1.96× s.e.m.; i.e., < 5% chance of false positive; Supplementary Table 6 ).
Imputation of clonal structures with bulk VAFs. The most common method used to impute clonal structure is based on the assumption that the most abundant mutation resides in the earliest-occurring ancestral clone. This method may be applicable to samples with linear clonal structures, but it may not be able to accurately resolve more complex or branching clonal structures. Longitudinal bulk genotyping data may offer additional information, particularly when there is evidence of clonal selection or evolution.
The putative clonal structure is first solved for each sample independently with the bulk VAF database according to the rules below. In samples for which there is no colony or SCG, longitudinal sampling (pre-ENA, best response and relapse) can provide additional information on the likely clonal structure of that patient. In the absence of colony or SCG data, bulk VAFs were used to estimate the size of the most likely clones in samples. In samples for which there was associated colony and/or SCG, the clonal structure was redrawn on the basis of these data, which provide a higher-confidence structure with some resolution of intermediate clones.
After this clonal structure was solved, bulk VAF was used to estimate the sizes of clones in samples.
The sequence of acquisition of mutations can be imputed from bulk genotyping data, by using VAF as an estimate of clonal contribution (Supplementary Fig. 11b ). Mutations are first ranked according to VAF: in these examples, V A is highest, and V D is lowest.
Factors that may cause data error and bias include limited cell-equivalent representation in extracted genomic DNA from small cell numbers, bias present in whole-genome-amplified material and PCR bias (including sequencing bias). Although we were unable to control for the first two factors, we were able to estimate the standard error of our sequencing data. We performed technicalreplicate genotyping of 19 unsorted BMMC populations and obtained the s.e.m. from VAFs from each mutation. In total, 142 s.e.m. values were obtained, and the average s.e.m. was 1.9% (range 0.0-20.2%), with a 95%-confidence-interval upper limit of 2.47%. This procedure limited our ability to reliably distinguish between clones varying in VAF by ~2.5% (~5% of cells if mutations were heterozygous), and we were not able to impute the sequence of acquisition of mutations in population genotyping with a < 2.5% difference in VAF between populations. When three or four mutations had VAF values within 2.5% of one another, the average VAF of the cluster was taken as the VAF of all mutations in that cluster (Supplementary Fig. 11c ).
Interpreting VAFs and cellular representation in the context of loss of heterozygosity or hemizygosity. We detected multiple occurrences of loss of heterozygosity (LoH, for example, copy-loss chromosomal deletions or copyneutral uniparental disomy) and mutations, which were on the X chromosome in male patients (hemizygosity). There is complexity in interpreting bulk VAFs, owing to the potential mix of cells with or without LoH within a bulk population. Notwithstanding this caveat, we used the simple models described below to help interpret VAFs in different contexts. For somatic heterozygous variants (somatic mutation or germline polymorphism) in autosomal chromosomes, the estimated percentage of cellular representation was 2× VAF% (Supplementary Fig. 11d ). Heterozygous variants and chromosomal deletion resulting in copy-loss LoH in autosomal chromosomes are illustrated in Supplementary Fig. 11e . Here, there was a nonlinear relationship between VAF and cellular representation ( Supplementary  Fig. 11f ). The formula that we used to estimate cellular representation was as follows: % cellular representation = [-2.777× (VAF ratio) 2 ] + (6.145× VAF ratio) -2.373. In heterozygous variants and copy-neutral LoH (for example, uniparental disomy) in autosomal chromosomes, the percentage cellular representation was 100% -(2× VAF%) (Supplementary Fig. 11g ). In X-linked variants in male subjects in sex chromosomes: the percentage cellular presentation was the same as the VAF% (Supplementary Fig. 11h ).
Determination of clonal structures with single-cell genotyping. Each single cell was assessed for detection or nondetection of mutations in that patient sample through amplicon sequencing of DNA subjected to WGA. A minimum coverage of 30× across amplicons was required for an amplicon to be called. We assigned the most likely sequence of acquisition of mutations on the basis of the genotype identified in cells. For example, when mutations A, B, C, D and E were identified in a sample, discrete cells with genotypes A, AB, ABC, ABD, ABCD and AE might be called. In most cases, the sequence of acquisition, for example, A → AB, is clear. However, the sequence of acquisition of mutations during the transition, for example, from AB to ABCD, may not be clear because of ADO; i.e., the sequence of acquisition may be AB → ABC → ABCD or AB → ABD → ABCD. In such cases, intermediate genotypes represented by most cells may be more likely to be true. In all cases, models of clonal structures that require the least number of discrete mutational steps required are represented 54 , although alternative structures, including ones in which the same mutation is acquired twice, are possible. After the most likely clonal structure is established, cells in which there was failure to amplify a locus that did not alter the assignment of a mutational complement (for example, an early mutation in the hierarchy) were included in the final analysis.
ADO estimation. ADO can be measured through two methods. First, ADO can be estimated by determining the phase of germline SNPs near mutations. For patients #201-023 and #201-011, we genotyped germline SNPs that were either in phase with (i.e., on the same allele as) a mutation or out of phase (i.e., on the opposite allele).
In-phase SNPs were rs6597996 and rs11246258, DEAF1 N372K mutation, patient #201-011. Out-of-phase SNPs were: (i) rs4911231, ASXL1 G646fs mutation, patient #201-023; (ii) rs2276598, DNMT3A R598X mutation, patient #201-011; (iii) rs7657364, DHX15 R222G mutation, patient #201-011. The SNPs were situated between 157 bases and 4 kb from the mutations. The threshold VAF for ascertaining dropout in these SNPs was < 2% (homozygous reference) or > 98% (homozygous variant).
In patient #201-023 (Fig. 3a,b) in two of three cells with the AS genotype, there was ADO of one of the IDH2 alleles ( Supplementary Fig. 12a , left) and in 2/12 cells with the genotype SI, there was ADO in the ASXL1 allele ( Supplementary Fig. 12a, right) .
Our analysis also showed that in patient #201-011 the mutations encoding R598X and R736C are on different DNMT3A alleles, and the R736C-encoding mutation is in phase with rs2276598 ( Supplementary Fig. 12b) .
By studying both VAFs of the SNP rs2276598 and the R736C mutation in cells with genotype DIA in patient #201-011 in which ADO might have occurred, we determined that in six of seven cells at CR, ADO of the allele encoding the R598X mutation had occurred ( Supplementary Fig. 12c left) . When the SNP did not amplify, the VAF of the R736C mutation was informative. Similarly, in the same patient at relapse, five of six DIA cells at relapse had ADO of the R598X-encoding allele ( Supplementary Fig. 12c center) . We also determined that in six of seven cells with the DIXF genotype at relapse, there had been ADO of the DHX15 allele encoding the R222G mutation ( Supplementary Fig. 12c, right) .
An alternate method to determine ADO more globally is to study the frequency with which a variant is called homozygous (either reference or alternative) when it should be heterozygous. We analyzed six SNPs in five genes (ASXL1, IDH2, DNMT3A, DEAF1 and DHX15) in 402 single cells from two patients (#201-011 and #201-023) known to be heterozygous in the germ line (as confirmed by genotyping a population of flow-cytometry-sorted T cells from the patients). The mean VAF was 49.1% for all six SNPs, and there was a nearsymmetrical distribution of VAFs across these single cells ranging from 0% to 100% (Supplementary Fig. 12d) Fig. 12d) .
Next, if mutations in patients were assumed to be heterozygous (i.e., in cases with no data to support uniparental disomy or copy-number loss), we determined the frequency at which mutations were called homozygous (VAF ≥ 99%) (presumably because of ADO). Across the 23 mutations assessed with this method, the average ADO rate of the wild-type allele was 10.36% (s.d. 5.7%; Supplementary Fig. 12e ). However, we found variation in ADO rates between different patients, even at the same mutation (for example, IDH2 R172K), thus suggesting that ADO is affected by factors in addition to that of the activity of the Phi21 polymerase. When possible, we used gene-specific germline SNPs or alternatively used sample-and mutation-specific ADO estimated by the 'homozygous mutant' method for our analyses.
Digital droplet PCR.
We confirmed the VAFs detected by NGS with digital droplet PCR in 17 amplicons and 113 sorted multicell AML populations from five patients with the Bio-Rad platform, as previously described 21 . There was good correlation between the VAF values obtained with these two methods (R 2 = 0.974,). There was one AML variant (DHX15 R222G) in which NGS yielded an unexpectedly high VAF in single normal BMMNCs (in which the mutation was found to be absent in the bulk normal BM sample). Detection of this variant in normal and AML samples was therefore carried out with digital droplet PCR, which indicated the presence of the mutation in AML bulk and single cells but confirmed its absence in normal bulk and single cells.
Whole-transcriptome sequencing (RNA-seq) and analysis of alternativesplicing events. Copy DNA libraries were prepared with extracted RNA from AML blast cells flow-cytometry sorted from re-and postrelapse samples from patients #201-011 and #201-013. cDNA libraries were prepared for sequencing with tagmentation and indexing with an Illumina Nextera Sample Preparation Kit. RNA-seq data were generated as 75-bp paired-end unstranded Illumina reads. Reads were aligned with STAR(v2.4.0.1) 55 to the human genome (GRCh37) with default parameters. On average, the alignment was 96.7% (range 95.5-97.4%) with an average of 139 × 10 6 (range: 116 × 10 6 to 169 × 10 6 ) mapped reads per sample. Differentially spliced events for the wild type (prerelapse) and postrelapse with spliceosome gene mutations analyzed as paired samples were identified 56 with Mixture of Isoforms (MISO v0.5.4) with default parameters. An event was termed differentially spliced if Bayes factor ≥ 10, and |Δ PSI| > 0.2, where PSI is the percentage spliced in, and the event is supported by ten or more reads. The classified differentially spliced events included skipped spliced exons, alternative 3′ /5′ splice sites, mutually exclusive exons and retained introns. 
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